In New Zealand, Singapore and USA
Suven Life Sciences announced that the Company has secured grant of one (1) product patent from New Zealand (619776), one (1) product patent from Singapore (2014003560) and one (1) product patent from USA (9079888) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032.The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of twenty four (24) granted patents from New Zealand, twenty two (22) granted product patents from Singapore and twenty two (22) granted patents from USA.
Powered by Capital Market - Live News